GAUCHER; Christine

Patent Applications and Registrations

Patent applications and USPTO patent grants for GAUCHER; Christine.The latest application filed is for "oral composition of anti-tnf-alpha antibodies".

Company Profile

2.14.18

GAUCHER; Christine - Sequedin FR
Gaucher; Christine - Equedin FR
Gaucher; Christine - Sequeden FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Oral Composition of Anti-TNF-Alpha Antibodies App 20190270801 - GAUCHER; Christine ; et al.	2019-09-05
Pharmaceutical compositions comprising an antibody which binds the human anti-Mullerian hormone receptor type II Grant 10,179,816 - Gaucher , et al. Ja	2019-01-15
Use of ADCC-optimized antibodies for treating low-responder patients Grant 9,879,089 - Bourel , et al. January 30, 2	2018-01-30
Antibody method for treatment of a disease in which the target cells are cells which express CD20 Grant 9,873,745 - De Romeuf , et al. January 23, 2	2018-01-23
Novel Pharmaceutical Compositions Comprising An Antibody Which Binds The Human Anti-mullerian Hormone Receptor Type Ii App 20170101478 - GAUCHER; Christine ; et al.	2017-04-13
Pharmaceutical compositions comprising an antibody which binds the human anti-mullerian hormone receptor type II Grant 9,511,138 - Gaucher , et al. December 6, 2	2016-12-06
Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations App 20160060350 - DE ROMEUF; Christophe ; et al.	2016-03-03
Monoclonal antibody directed against CD20 antigen Grant 9,234,045 - De Romeuf , et al. January 12, 2	2016-01-12
Use Of Adcc-optimized Antibodies For Treating Weak Patients App 20150307624 - Bourel; Dominique ; et al.	2015-10-29
Use of ADCC-optimized antibodies for treating weak patients Grant 9,109,020 - Bourel , et al. August 18, 2	2015-08-18
Novel Pharmaceutical Compositions Comprising An Antibody Which Binds The Human Anti-mullerian Hormone Receptor Type Ii App 20150004156 - Gaucher; Christine ; et al.	2015-01-01
Use Of Adcc-optimized Antibodies For Treating Weak Patients App 20140017243 - Bourel; Dominique ; et al.	2014-01-16
Use of ADCC-optimized antibodies for treating weak patients Grant 8,501,171 - Bourel , et al. August 6, 2	2013-08-06
Anti-rhesus D monoclonal antibody Grant 8,404,241 - Gaucher , et al. March 26, 2	2013-03-26
Anti-rhesus D Monoclonal Antibody App 20110311556 - Gaucher; Christine ; et al.	2011-12-22
Cytotoxic Antibodies Directed Against Antibodies Inhibiting Factor Viii App 20110274684 - BEHRENS; Christian ; et al.	2011-11-10
Cytotoxic antibodies directed against antibodies inhibiting factor VIII Grant 8,038,993 - Behrens , et al. October 18, 2	2011-10-18
Cytokine production-inducing antibody App 20100323368 - de Romeuf; Christophe ; et al.	2010-12-23
Use of ADCC-Optimized antibodies for treating weak patients App 20100303826 - Bourel; Dominique ; et al.	2010-12-02
Use of ADCC-optimized antibodies for treating low-responder patients Grant 7,713,524 - Bourel , et al. May 11, 2	2010-05-11
Method of measuring activation of effector cells Grant 7,595,165 - Romeuf , et al. September 29, 2	2009-09-29
Antibody raised against the ldl receptor App 20090175789 - Behrens; Christian ; et al.	2009-07-09
Cytotoxic Antibodies Directed Against Antibodies Inhibiting Factor VIII App 20090130094 - Behrens; Christian ; et al.	2009-05-21
Treatment Of Pathologies Which Escape The Immune Response, Using Optimized Antibodies App 20090081216 - de ROMEUF; Christophe ; et al.	2009-03-26
Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations App 20090053233 - De Romeuf; Christophe ; et al.	2009-02-26
Use of adcc-optimized antibodies for treating weak patients App 20060182741 - Bourel; Dominique ; et al.	2006-08-17
Treatment of pathologies which escape the immune response, using optimised antibodies App 20050271652 - de Romeuf, Christophe ; et al.	2005-12-08
Cytokine production-inducing antibody App 20050249732 - de Romeuf, Christophe ; et al.	2005-11-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.